Revolution Medicines (RVMD) Amortization of Deferred Charges (2020 - 2026)

Revolution Medicines (RVMD) recorded quarterly Amortization of Deferred Charges of $12.2 million in Q1 2026, up 2.18% quarter-over-quarter from $11.9 million in Q4 2025.

Revolution Medicines (RVMD) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends

Revolution Medicines' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $12.2 million for Q1 2026.

  • In Q1 2026, Amortization of Deferred Charges changed N/A year-over-year to $12.2 million; the TTM figure through Mar 2026 stood at $36.4 million (up 3620.94% YoY), while the FY2025 annual figure was $24.2 million, changed N/A from the prior year.
  • Amortization of Deferred Charges was $12.2 million for Q1 2026 at Revolution Medicines, up from $11.9 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $12.2 million in Q1 2026 to a low of $866000.0 in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Revolution Medicines 32.33 Bn 32.33 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 12.20 Mn
Mar 31, 2026 12.20 Mn
Dec 31, 2025 11.94 Mn
Dec 31, 2025 11.94 Mn
Sep 30, 2025 11.43 Mn
Sep 30, 2025 11.43 Mn
Jun 30, 2025 866,000.00
Jun 30, 2025 866,000.00
Dec 31, 2021 979,000.00
Dec 31, 2021 979,000.00
Sep 30, 2021 691,000.00
Sep 30, 2021 691,000.00
Jun 30, 2021 770,000.00
Jun 30, 2021 770,000.00
Mar 31, 2021 740,000.00
Mar 31, 2021 740,000.00
Dec 31, 2020 759,000.00
Dec 31, 2020 759,000.00
Sep 30, 2020 698,000.00
Sep 30, 2020 698,000.00